指南与共识消化、代谢与肾脏急症重症综合管理与镇静镇痛

北美专家意见声明:肝移植中的肌肉减少症

A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation.
指南 / 共识 · Hepatology · 2019-08-19
一句话结论对所有接受肝移植评估的肝硬化患者应考虑肌肉减少症评估,CT测骨骼肌指数男性<50 cm²/m²、女性<39 cm²/m²为已验证定义。

该专家意见声明由北美肝移植肌肉减少症工作组制定,指出肌肉量减少是肝硬化常见特征,与不良结局相关,包括生活质量差、肝硬化失代偿、肝移植评估患者死亡率、住院和ICU时间延长、移植后感染发生率增高及总体医疗费用增高。声明认为所有接受肝移植评估的肝硬化患者应考虑肌肉减少症评估,CT测骨骼肌指数是研究最多的技术,男性<50 cm²/m²、女性<39 cm²/m²为已验证定义。结论指出肌肉减少症管理需多管齐下,包括营养、运动及必要时额外药物治疗。

要点

  • 所有接受肝移植评估的肝硬化患者应考虑肌肉减少症评估。
  • CT测骨骼肌指数是肝硬化患者肌肉减少症研究最多的评估技术。
  • 肌肉减少症已验证定义为骨骼肌指数男性<50 cm²/m²、女性<39 cm²/m²。
  • 肌肉减少症与肝硬化患者生活质量差、失代偿、肝移植评估患者死亡率、住院和ICU时间延长、移植后感染发生率增高及医疗费用增高相关。
  • 肌肉减少症管理需多管齐下,包括营养、运动及必要时额外药物治疗。

适用人群与场景

  • 接受肝移植评估的肝硬化患者。

诊断标准与关键阈值

  • 肌肉减少症定义:CT测骨骼肌指数男性<50 cm²/m²、女性<39 cm²/m²,为肝硬化患者已验证的定义。

处置流程与药物剂量

  • 肌肉减少症管理需多管齐下,包括营养、运动及必要时额外药物治疗。

研究设计与关键结果

  • 北美肝移植肌肉减少症工作组汇集专家,利用医学文献证据解决肝移植中肌肉减少症的未决问题,包括最佳评估方式、最佳截断值、理想评估时机和频率以及如何将肌肉减少症概念纳入临床决策。

证据类型、等级与局限

  • 证据类型:专家意见声明。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为所有接受肝移植评估的肝硬化患者应考虑肌肉减少症评估。
  • 作者认为CT测骨骼肌指数是肝硬化患者肌肉减少症研究最多的技术,男性<50 cm²/m²、女性<39 cm²/m²为已验证定义。
  • 作者认为肌肉减少症管理需多管齐下,包括营养、运动及必要时额外药物治疗。

指南或共识出处

  • 北美肝移植肌肉减少症工作组专家意见声明(A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Loss of muscle mass and function, or sarcopenia, is a common feature of cirrhosis and contributes significantly to morbidity and mortality in this population. Sarcopenia is a main indicator of adverse outcomes in this population, including poor quality of life, hepatic decompensation, mortality in patients with cirrhosis evaluated for liver transplantation (LT), longer hospital and intensive care unit stay, higher incidence of infection following LT, and higher overall health care cost. Although it is clear that muscle mass is an important predictor of LT outcomes, many questions remain, including the best modality for assessing muscle mass, the optimal cut-off values for sarcopenia, the ideal timing and frequency of muscle mass assessment, and how to best incorporate the concept of sarcopenia into clinical decision making. For these reasons, we assembled a group of experts to form the North American Working Group on Sarcopenia in Liver Transplantation to use evidence from the medical literature to address these outstanding questions regarding sarcopenia in LT. We believe sarcopenia assessment should be considered in all patients with cirrhosis evaluated for liver transplantation. Skeletal muscle index (SMI) assessed by computed tomography constitutes the best-studied technique for assessing sarcopenia in patients with cirrhosis. Cut-off values for sarcopenia, defined as SMI < 50 cm2 /m2 in male and < 39 cm2 /m2 in female patients, constitute the validated definition for sarcopenia in patients with cirrhosis. Conclusion: The management of sarcopenia requires a multipronged approach including nutrition, exercise, and additional pharmacological therapy as deemed necessary. Future studies should evaluate whether recovery of sarcopenia with nutritional management in combination with an exercise program is sustainable as well as how improvement in muscle mass might be associated with improvement in clinical outcomes.

来源:Hepatology,查看原文。版权归原作者所有。

参考来源

  1. Carey EJ, Lai JC, Sonnenday C, et al. A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation. Hepatology. 2019. PMID: 31220351. doi:10.1002/hep.30828

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。